Global Drugs for Vulvovaginal Candidiasis Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Global Drugs for Vulvovaginal Candidiasis Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Table of Contents
1 Study Coverage
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Market by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2016-2027
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027
2.2 Drugs for Vulvovaginal Candidiasis Market Size by Region: 2021 Versus 2027
2.3 Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2027)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2016-2021
2.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2027)
2.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2016-2021
2.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027)
2.4.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
3 Global Drugs for Vulvovaginal Candidiasis by Manufacturers
3.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2021)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue
3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2021)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2016-2021)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2021)
3.4 Competitive Landscape
3.4.1 Key Drugs for Vulvovaginal Candidiasis Manufacturers Covered: Ranking by Revenue
3.4.2 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI) & (2016-2021)
3.4.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Type
3.5.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
3.5.3 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Bayer
4.1.1 Bayer Corporation Information
4.1.2 Bayer Description, Business Overview
4.1.3 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
4.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.1.5 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Product
4.1.6 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Application
4.1.7 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.1.8 Bayer Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.1.9 Bayer Recent Development
4.2 Perrigo
4.2.1 Perrigo Corporation Information
4.2.2 Perrigo Description, Business Overview
4.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
4.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.2.5 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Product
4.2.6 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Application
4.2.7 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.2.8 Perrigo Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.2.9 Perrigo Recent Development
4.3 J & J
4.3.1 J & J Corporation Information
4.3.2 J & J Description, Business Overview
4.3.3 J & J Drugs for Vulvovaginal Candidiasis Products Offered
4.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.3.5 J & J Drugs for Vulvovaginal Candidiasis Revenue by Product
4.3.6 J & J Drugs for Vulvovaginal Candidiasis Revenue by Application
4.3.7 J & J Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.3.8 J & J Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.3.9 J & J Recent Development
4.4 Pfizer
4.4.1 Pfizer Corporation Information
4.4.2 Pfizer Description, Business Overview
4.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
4.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.4.5 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Product
4.4.6 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Application
4.4.7 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.4.8 Pfizer Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.4.9 Pfizer Recent Development
4.5 Bristol-Myers Squibb
4.5.1 Bristol-Myers Squibb Corporation Information
4.5.2 Bristol-Myers Squibb Description, Business Overview
4.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
4.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.5.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Product
4.5.6 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Application
4.5.7 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.5.8 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue by Sales Channel
4.5.9 Bristol-Myers Squibb Recent Development
4.6 Effik
4.6.1 Effik Corporation Information
4.6.2 Effik Description, Business Overview
4.6.3 Effik Drugs for Vulvovaginal Candidiasis Products Offered
4.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.6.5 Effik Drugs for Vulvovaginal Candidiasis Revenue by Product
4.6.6 Effik Drugs for Vulvovaginal Candidiasis Revenue by Application
4.6.7 Effik Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.6.8 Effik Recent Development
4.7 Teva
4.7.1 Teva Corporation Information
4.7.2 Teva Description, Business Overview
4.7.3 Teva Drugs for Vulvovaginal Candidiasis Products Offered
4.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.7.5 Teva Drugs for Vulvovaginal Candidiasis Revenue by Product
4.7.6 Teva Drugs for Vulvovaginal Candidiasis Revenue by Application
4.7.7 Teva Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.7.8 Teva Recent Development
4.8 Sanofi
4.8.1 Sanofi Corporation Information
4.8.2 Sanofi Description, Business Overview
4.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
4.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.8.5 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Product
4.8.6 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Application
4.8.7 Sanofi Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.8.8 Sanofi Recent Development
4.9 Cisen Pharmaceutical
4.9.1 Cisen Pharmaceutical Corporation Information
4.9.2 Cisen Pharmaceutical Description, Business Overview
4.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
4.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.9.5 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Product
4.9.6 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Application
4.9.7 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.9.8 Cisen Pharmaceutical Recent Development
4.10 Kingyork Group
4.10.1 Kingyork Group Corporation Information
4.10.2 Kingyork Group Description, Business Overview
4.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
4.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
4.10.5 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Product
4.10.6 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Application
4.10.7 Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue by Geographic Area
4.10.8 Kingyork Group Recent Development
5 Breakdown Data by Type
5.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2027)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2027)
5.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2016-2027)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2016-2027)
5.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2027)
6 Breakdown Data by Application
6.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2027)
6.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021)
6.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027)
6.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2027)
6.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2016-2027)
6.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021)
6.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027)
6.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2016-2027)
6.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2016-2027)
7 North America
7.1 North America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
7.2 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
7.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
7.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
7.3 North America Drugs for Vulvovaginal Candidiasis Sales by Type
7.4 North America Drugs for Vulvovaginal Candidiasis Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
8.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
8.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2027)
8.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2027)
8.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type
8.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application
9 Europe
9.1 Europe Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
9.2 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
9.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
9.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
9.3 Europe Drugs for Vulvovaginal Candidiasis Sales by Type
9.4 Europe Drugs for Vulvovaginal Candidiasis Sales by Application
10 Latin America
10.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
10.2 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
10.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
10.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
10.3 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type
10.4 Latin America Drugs for Vulvovaginal Candidiasis Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
11.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2027)
11.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2027)
11.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type
11.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
12.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
12.3 Drugs for Vulvovaginal Candidiasis Clients Analysis
12.4 Drugs for Vulvovaginal Candidiasis Sales Channel and Sales Model Analysis
12.4.1 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Drugs for Vulvovaginal Candidiasis Distributors
13 Market Dynamics
13.1 Drugs for Vulvovaginal Candidiasis Market Drivers
13.2 Drugs for Vulvovaginal Candidiasis Market Opportunities
13.3 Drugs for Vulvovaginal Candidiasis Market Challenges
13.4 Drugs for Vulvovaginal Candidiasis Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
Table 2. Major Manufacturers of Cream
Table 3. Major Manufacturers of Pessary
Table 4. Major Manufacturers of Other
Table 5. Global Drugs for Vulvovaginal Candidiasis Market Size Growth by Application (US$ Million): 2021 VS 2027
Table 6. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2021 VS 2027
Table 7. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021) & (K Units)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027) & (K Units)
Table 9. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2021) & (US$ Million)
Table 10. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 11. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2021) & (K Units)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer (2016-2021)
Table 13. Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2021) & (US$ Million)
Table 14. Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2016-2021)
Table 15. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2016-2021) & (USD/Unit)
Table 16. Ranking of Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (US$ Million) in 2020
Table 17. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 18. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2020)
Table 19. Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 21. Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Bayer Corporation Information
Table 24. Bayer Description and Business Overview
Table 25. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 26. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 27. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 28. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 29. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 30. Bayer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 31. Bayer Recent Development
Table 32. Perrigo Corporation Information
Table 33. Perrigo Description and Business Overview
Table 34. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 35. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 36. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 37. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 38. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 39. Perrigo Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 40. Perrigo Recent Development
Table 41. J & J Corporation Information
Table 42. J & J Description and Business Overview
Table 43. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 44. J & J Drugs for Vulvovaginal Candidiasis Product
Table 45. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 46. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 47. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 48. J & J Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 49. J & J Recent Development
Table 50. Pfizer Corporation Information
Table 51. Pfizer Description and Business Overview
Table 52. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 53. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 54. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 55. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 56. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 57. Pfizer Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 58. Pfizer Recent Development
Table 59. Bristol-Myers Squibb Corporation Information
Table 60. Bristol-Myers Squibb Description and Business Overview
Table 61. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 62. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 63. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 64. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 65. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 66. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Sales Channel
Table 67. Bristol-Myers Squibb Recent Development
Table 68. Effik Corporation Information
Table 69. Effik Description and Business Overview
Table 70. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Effik Drugs for Vulvovaginal Candidiasis Product
Table 72. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 73. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 74. Effik Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 75. Effik Recent Development
Table 76. Teva Corporation Information
Table 77. Teva Description and Business Overview
Table 78. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 79. Teva Drugs for Vulvovaginal Candidiasis Product
Table 80. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 81. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 82. Teva Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 83. Teva Recent Development
Table 84. Sanofi Corporation Information
Table 85. Sanofi Description and Business Overview
Table 86. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 87. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 88. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 89. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 90. Sanofi Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 91. Sanofi Recent Development
Table 92. Cisen Pharmaceutical Corporation Information
Table 93. Cisen Pharmaceutical Description and Business Overview
Table 94. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 95. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 96. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 97. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 98. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 99. Cisen Pharmaceutical Recent Development
Table 100. Kingyork Group Corporation Information
Table 101. Kingyork Group Description and Business Overview
Table 102. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 104. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Product
Table 105. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Application
Table 106. Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) and Market Share by Geographic Area
Table 107. Kingyork Group Recent Development
Table 108. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 109. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027) & (K Units)
Table 110. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021) & (US$ Million)
Table 111. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 112. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 113. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027) & (K Units)
Table 114. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021) & (US$ Million)
Table 115. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 116. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 117. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 118. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 119. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 120. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 121. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 122. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021) & (K Units)
Table 123. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2022-2027) & (K Units)
Table 124. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2027) & (US$ Million)
Table 125. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2022-2027) & (US$ Million)
Table 126. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 127. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 128. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 129. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 130. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 131. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 132. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 133. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 134. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 135. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 136. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 137. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 138. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 139. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 140. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 141. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2022-2027) & (K Units)
Table 142. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 143. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2022-2027) & (US$ Million)
Table 144. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 145. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 146. Drugs for Vulvovaginal Candidiasis Key Raw Materials, Industry Status and Trend
Table 147. Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
Table 148. Drugs for Vulvovaginal Candidiasis Clients Status and Trend
Table 149. Drugs for Vulvovaginal Candidiasis Typical Clients
Table 150. Drugs for Vulvovaginal Candidiasis Distributors
Table 151. Key Drivers: Impact Analysis (2022-2027)
Table 152. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 153. Drugs for Vulvovaginal Candidiasis Market Opportunities
Table 154. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 155. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 156. Drugs for Vulvovaginal Candidiasis Porter's Five Forces Analysis
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2021 & 2027
Figure 3. Cream Product Picture
Figure 4. Pessary Product Picture
Figure 5. Other Product Picture
Figure 6. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2021 & 2027
Figure 7. Hospital & Clinic Examples
Figure 8. Pharmacy Examples
Figure 9. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 10. Global Drugs for Vulvovaginal Candidiasis Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Drugs for Vulvovaginal Candidiasis Market Size 2016-2027 (US$ Million)
Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027 (K Units)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Region: 2021 Versus 2027
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2016-2027)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
Figure 16. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer in 2020
Figure 17. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2016-2027)
Figure 19. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2016-2027)
Figure 20. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2016-2027)
Figure 22. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2016-2027)
Figure 23. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Figure 24. North America Drugs for Vulvovaginal Candidiasis Revenue 2016-2027 (US$ Million)
Figure 25. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 26. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 27. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue 2016-2027 (US$ Million)
Figure 28. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2027)
Figure 29. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2027)
Fi

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119

According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......

Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132

According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......

Global Contraceptives Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141

According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......

Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108

According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......

Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99

Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......

Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139

Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122

Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......

Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108

Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......

Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123

Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs